In this webinar on optimising triage of HPV-positive patients with the use of  p16/Ki67 dual staining biomarkers, two experts from Singapore General Hospital share their experiences with the use of this triage method. Prof Tay Sun Kuie, Clinical Professor and Senior Consultant OB/GYN and Dr Sangeeta Mantoo, Senior Consultant at the Department of Anatomical Pathology, tell of the value of p16/Ki67 dual staining biomarkers from their respective ends of the diagnostic journey.

Prof Tay highlights that the IMPACT trial and a 245-sample study conducted at SGH yielded similar observations, confirming that a negative dual staining result indicates a low risk of pre-cancer even in HPV-positive patients. This brings more assurance to healthcare practitioners when managing their patient’s risk of cervical cancer.  With this triage method, Prof Tay lays out a health economics model and analysis for a screening algorithm which combines the use of HPV primary screening with dual stain for triage, whereby the incorporation of dual stain would result in a significant reduction in interventions, reducing costs on the national health system.

As an anatomical pathologist, Dr Mantoo speaks at length about the nuances seen in the staining of HPV-positive samples with p16/Ki67 dual staining biomarkers with the use of real-life examples. In her session, she discusses how her team reports results from dual staining and management of unsatisfactory results. To ensure the integrity of results, she also discusses quality measures that are undertaken in her lab, from training and support by assay manufacturers to the establishment of in-house quality assurance programmes.

The full webinar can be accessed, along with the Q&A portion. The timings of each session have been marked for you in the playbar.